January 17, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) shares over potential securities laws violations by Fresenius Medical Care AG & Co. and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) concerning whether a series of statements by Fresenius Medical Care AG & Co. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Fresenius Medical Care AG & Co. reported that its annual Total Revenue rose from over $15.83 billion in 2014 to over $16.73 billion in 2015 and that its Net Income declined from over $1.04 billion in 2014 to over $1.02 billion in 2015.

Shares of Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) reached as high as $47.09 per share in August 2016.

On January 7, 2017, Fresenius Medical Care AG & Co. reported that its U.S. unit had received subpoenas from federal prosecutors seeking information on the Company's ties with the American Kidney Fund, a charity that helps patients pay for kidney dialysis.

Shares of Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) closed on January 17, 2017 at $40.93 per share.